Contineum reports Q3 2026 results, PROPEL-IPF enrollment expands to over 100 sites
Contineum said its Phase 2 IPF trial of PIPE-791 now spans more than 100 sites in 16 countries, with cash runway projected through mid-2029.
SEC filing
2 stories
Contineum said its Phase 2 IPF trial of PIPE-791 now spans more than 100 sites in 16 countries, with cash runway projected through mid-2029.
SEC filing
JNJ-5120/PIPE-307, licensed to Johnson & Johnson, missed its primary efficacy measure in major depressive disorder, though the company reported no new safety signals.
SEC filing